Abstract
IntroductionTherapeutic options for children with severe asthma are limited. Clinical studies support the use of the anti-IgE antibody, omalizumab, in children with severe atopic asthma. However, children included in these...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
